June 5, 2026 · Last updated: June 5, 2026
FDA Moves to Bar Outsourcing Facilities From Bulk-Compounding Semaglutide, Tirzepatide, and Liraglutide
The agency found no clinical need to keep the three leading GLP-1 drugs available for large-scale 503B bulk compounding. A public comment window runs through June 29 — here’s what the proposal does, and doesn’t, cover.
On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the regulatory mechanism that governs which active ingredients FDA-registered outsourcing facilities may use in large-scale compounding. After reviewing the nominations for all three, the agency said it found no demonstrated clinical need for outsourcing facilities to compound them from bulk substances. The proposal was formalized in a May 1 Federal Register notice (91 Fed. Reg. 23431).
The mechanics matter. A 503B outsourcing facility can generally only compound from a bulk substance if that substance is on the 503B bulks list, or if the finished drug is on the FDA’s shortage list. Semaglutide came off the shortage list in 2025 and tirzepatide in 2024 — so for those two, excluding them from the bulks list removes the last remaining pathway for bulk compounding. Liraglutide injection currently remains on the shortage list, so it can still be compounded by 503B facilities for now despite its absence from the bulks list.
What the proposal does not touch is just as important: it applies to 503B outsourcing facilities, not 503A compounding pharmacies, and it doesn’t change the shortage-era rules. FDA Commissioner Marty Makary framed the action around the principle that when FDA-approved drugs are available, outsourcing facilities cannot lawfully compound from bulk substances “unless there is a clear clinical need.”
The safety backdrop is part of the agency’s rationale — adverse-event reports tied to compounded GLP-1s, dosing errors from multi-dose vials, manufacturer litigation alleging impurities in compounded semaglutide, and warning letters to telehealth firms marketing compounded copies as equivalent to the branded drugs.
For the research community, two things are worth keeping straight. This is a distinct regulatory track from the Category 2 peptide compounding question headed to the FDA’s July advisory committee, and separate again from the broader peptide-access shifts under discussion this year. And it has no bearing on retatrutide, which was never eligible for compounding in the first place — there’s no approved version, so no shortage pathway ever applied.
The comment window runs through June 29, 2026, after which the FDA will weigh the input before a final determination.
Sources
This article is for informational and educational purposes only and does not constitute medical or legal advice. It summarizes a proposed FDA action that is open for public comment and is not a final rule. All research compounds referenced are for laboratory use only.
Have a question about FDA Moves to Bar Outsourcing Facilities From Bulk-Compounding Semaglutide, Tirzepatide, and Liraglutide? Send us an email →